Braveheart files for IPO to fund Phase 3 of Hengrui's Cytokinetics rival

Braveheart CEO Travis Murdoch July 15, 2026 08:52 AM EDT StartupsChinaIPOs Brave­heart files for IPO to fund Phase 3 of Hen­grui's Cy­to­ki­net­ics ri­val Kyle LaHucik Biotech Correspondent Biotechs are sprint­ing to the IPO queue. In the in­dus­try’s fourth IPO fil­ing in two weeks, Brave­heart Bio is seek­ing a Nas­daq list­ing to fu­el … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER